SCHEMBL20512871

SCHEMBL20512871

COCC1(c2ccc(Br)cc2)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4C Q9H3R0 1/20 0.35
TACR1 P25103 3/20 0.34
HPGD P15428 1/20 0.33
F10 P00742 1/20 0.33
P2RY1 P47900 1/20 0.33
SLC6A4 P31645 3/20 0.33
KCNH2 Q12809 2/20 0.33
DGAT1 O75907 1/20 0.33
ALDH1A1 P00352 2/20 0.33
CHRM2 P08172 1/20 0.33
CHRM1 P11229 1/20 0.33
LMNA P02545 1/20 0.33
POLB P06746 1/20 0.33
MAPK1 P28482 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
SLC6A2 P23975 1/20 0.33
SLC6A3 Q01959 1/20 0.33
TAAR1 Q96RJ0 2/20 0.32
MAOA P21397 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2325066 0.92 CHRM2 (0.37) TACR1SLC6A4ALDH1A1CHRM2CHRM1
SCHEMBL2636513 0.92 CHRM2 (0.40) SLC6A4ALDH1A1CHRM2CHRM1LMNA
SCHEMBL1120946 0.88 SMN1; SMN2 (0.41) ALDH1A1LMNAPOLBSMN1; SMN2L3MBTL1
SCHEMBL8353676 0.82 L3MBTL1 (0.36) KDM4CTACR1F10P2RY1SLC6A4
SCHEMBL11890684 0.81 CHRM2 (0.40) TACR1HPGDSLC6A4KCNH2CHRM2
SCHEMBL12345187 0.80 ESR2 (0.42) KDM4CTACR1F10P2RY1SLC6A4
SCHEMBL14458411 0.80 F10 (0.45) TACR1F10SLC6A4ALDH1A1CHRM1
SCHEMBL19402984 0.79 MAOA (0.54) TACR1SLC6A4CHRM2CHRM1SLC6A2
SCHEMBL12980759 0.78 CHRM2 (0.44) TACR1HPGDSLC6A4KCNH2ALDH1A1
SCHEMBL5175812 0.77 KDM1A (0.39) SLC6A4ALDH1A1LMNAPOLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2025-10-07 US disclosed
CN-110740991-B Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2023-07-04 CN disclosed
EP-3632443-B1 ANTI-TUMOR EFFECT POTENTIATOR USING A BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO LTD (JP) 2023-06-07 EP disclosed
EP-3381896-B1 BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO LTD (JP) 2023-01-18 EP disclosed
US-11510915-B2 Anti-tumor effect potentiator using novel biphenyl compound TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-11-29 US disclosed
US-11479563-B2 Biphenyl compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2022-10-25 US disclosed
CN-108602770-B Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2022-02-08 CN disclosed
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND TAIHO PHARMACEUTICAL CO., LTD. (JP) 2021-06-17 US disclosed
US-10723742-B2 Biphenyl compound or salt thereof TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-07-28 US disclosed
US-20200190175-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 TAIHO PHARMACEUTICAL CO., LTD. (JP) 2020-06-18 US disclosed
EP-3632443-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
EP-3632897-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
EP-3633380-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 Taiho Pharmaceutical Co., Ltd. (JP) 2020-04-08 EP disclosed
CN-110740991-A Novel biphenyl compound or salt thereof 大鹏药品工业株式会社 2020-01-31 CN disclosed
US-20180354960-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF TAIHO PHARMACEUTICAL CO., LTD. (JP) 2018-12-13 US disclosed
EP-3381896-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF Taiho Pharmaceutical Co., Ltd. (JP) 2018-10-03 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210177826-A1 ANTI-TUMOR EFFECT POTENTIATOR USING NOVEL BIPHENYL COMPOUND KDM1B, KDM1A, DOT1L KDM4C 29/4885TACR1 2931/4885HPGD 3912/4885
US-10723742-B2 Biphenyl compound or salt thereof KDM1B, BMI1, HDAC1 KDM4C 37/4885TACR1 3494/4885HPGD 2568/4885
US-11479563-B2 Biphenyl compound or salt thereof BMI1, KDM1B, KDM1A KDM4C 33/4885TACR1 2678/4885HPGD 3226/4885
US-12435128-B2 Method for predicting therapeutic effect of LSD1 inhibitor based on expression of INSM1 INMT, CARM1, KDM1B KDM4C 50/4885TACR1 4596/4885HPGD 3010/4885
US-20200190175-A1 METHOD FOR PREDICTING THERAPEUTIC EFFECT OF LSD1 INHIBITOR BASED ON EXPRESSION OF INSM1 INMT, CARM1, KDM1B KDM4C 50/4885TACR1 4596/4885HPGD 3010/4885
US-20180354960-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF KDM1B, HDAC1, DOT1L KDM4C 42/4885TACR1 3975/4885HPGD 2913/4885
US-11510915-B2 Anti-tumor effect potentiator using novel biphenyl compound KDM1B, KDM1A, DOT1L KDM4C 29/4885TACR1 2931/4885HPGD 3912/4885
US-20210179634-A1 NOVEL BIPHENYL COMPOUND OR SALT THEREOF KDM1B, KDM1A, HDAC1 KDM4C 34/4885TACR1 3228/4885HPGD 3367/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.